A registered dietitian offers strategies and shortcuts to help you get your meals and snacks on track.

Record numbers of Americans are dying of opioid overdoses, yet medication-assisted treatment is utilized far too infrequently. Cigna Healthcare is working to change that as part of a strategy to reduce overdoses from drugs such as fentanyl, heroin, and oxycodone.

These simple steps can protect you, your loved ones, and your community during flu season.

How can parents determine if their children may need professional help with behavioral problems? Cigna’s Dr. Stuart Lustig, a child psychiatrist, offers his insights and advice.

Looking for a Medicare Advantage plan? Understanding star ratings – and knowing where to find them – can help you select the plan that's best for you.

Dr. Leslie Barakat, a pediatrician and senior medical director for Cigna, has advice about keeping children as safe as possible now that they are back in the classroom.

As virtual health care continues to grow, physicians and patients are utilizing technology to build relationships. We interviewed Dr. Vontrelle Roundtree, MDLIVE’s interim chief medical officer, to share her thoughts about the doctor-patient relationship and how it can thrive with virtual care.

Americans with employer-sponsored health insurance want plans that cover behavioral and physical health care needs, according to a new AHIP survey.

Scams are rampant in today’s world, in health care and other areas. While anyone of any age can be targeted, older adults are particularly at risk. Last year, fraud cost U.S. seniors more than $1.5 billion. Here is some advice that can help older adults – and younger people, too – protect themselves from scams.

Biosimilars represent a meaningful opportunity to reduce drug spending by as much as $375 billion over the next decade. Cigna is committed to driving greater value and lower costs where clinically appropriate for our customers and clients. As a longtime advocate for greater availability of biosimilars, we have worked for a decade to advance the pathways needed to bring biosimilars to market.